$3.75 BillionThe market capitalization is the market value of the company. It is the sum of the value of all outstanding shares.
$42.5 MillionTotal revenue in the last quarter.
$-61.9 MillionNet income is all revenues minus all expenses including taxes and interest in the last quarter.
$-2.65Earnings per share is the amount of net income that is attributed to each single share outstanding.
-Dividends per share is the amount of dividends paid out to the shareholder of a single share in the last 12 months. The percentage indicates the ratio of the company's annual dividend compared to its current price per share (stock price).
-13.95xThe price-earnings ratio is the ratio between the price per share (stock price) and the earnings per share. It indicates the percentage of the price per share (stock price) that is generated in earnings in the last 12 months.
$-54.1 MillionEarnings before interest expenses and taxes in the last quarter.
435The number of full time employees.
Insmed, Inc. is a biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Its first commercial product is ARIKAYCE (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options. The MAC lung disease is a rare and often chronic infection that can cause irreversible lung damage and can be fatal. Its earlier-stage clinical pipeline includes INS1007, a novel oral reversible inhibitor of dipeptidyl peptidase 1 with therapeutic potential in non-cystic fibrosis bronchiectasis and other inflammatory diseases, and INS1009, an inhaled formulation of a treprostinil prodrug that may offer a differentiated product profile for rare pulmonary disorders, including pulmonary arterial hypertension. The company was founded in 1988 and is headquartered in Bridgewater, NJ.
BidaskClub upgraded shares of Insmed (NASDAQ:INSM) from a hold rating to a buy rating in a report published on Wednesday morning, BidAskClub reports. INSM has been the subject of a number of other ...Dispatch Tribunal, 1 day ago
Insmed (NASDAQ:INSM) will be posting its quarterly earnings results before the market opens on Thursday, October 29th. Analysts expect Insmed to post earnings of ($0.59) per share for the quarter. ...Daily Political, 4 days ago
BRIDGEWATER, N.J., Sept. 30, 2020 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseas...PR Newswire, 25 days ago